(S1 (S (S (NP (DT The) (JJ antiangiogenic) (NN agent) (NN linomide)) (VP (VBZ inhibits) (NP (NP (DT the) (NN growth) (NN rate)) (PP (IN of) (NP (NN von) (NN Hippel-Lindau) (NN paraganglioma) (NNS xenografts))) (PP (TO to) (NP (NNS mice)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB ascertain) (NP (NP (DT the) (JJ potential) (NN usefulness)) (PP (IN of) (NP (DT the) (JJ antiangiogenic) (NN compound) (NN linomide))) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (ADJP (NN von) (NN Hippel-Lindau) (-LRB- -LRB-) (NN VHL) (-RRB- -RRB-) (JJ -related)) (NNS tumors))))))))))) (. .)))
(S1 (S (S (S (NP (NP (NN Paraganglioma) (NN tissue) (NNS fragments)) (VP (VBN obtained) (PP (IN at) (NP (NN surgery))) (PP (IN from) (NP (DT a) (NN VHL) (NN type) (NN 2a) (NN patient))))) (VP (VBD were) (VP (VBN transplanted) (NP (NN s.c.)) (PP (TO to) (NP (JJ male) (NN BALB/c) (NN nu/nu) (-LRB- -LRB-) (JJ nude) (-RRB- -RRB-) (NNS mice)))))) (: :) (NP (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-)) (NP (JJ 2-3-mm) (NNS fragments)) (PP (IN for) (NP (NP (`` ``) (NN prevention) ('' '')) (NNS experiments)))) (: ;) (CC and) (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-)) (S (NP (JJ 2-3-mm) (NNS fragments)) (VP (VBD allowed) (S (VP (TO to) (VP (VB grow) (PP (TO to) (NP (NP (CD 1) (NN cm)) (PP (IN for) (NP (`` ``) (NN intervention) (POS '') (NNS studies))))))))))) (. .)))
(S1 (S (S (NP (DT Both) (NNS groups)) (VP (VP (VBD received) (NP (DT either) (ADJP (CD 0.5) (NN mg/ml)) (NN linomide)) (PP (IN in) (S (VP (VBG drinking) (NP (NP (NN water)) (CC or) (NP (JJ acidified) (NN water))))))) (CC and) (VP (VBD were) (VP (VBN followed) (PP (PP (IN until) (NP (NP (NN tumor) (NN diameter)) (VP (VBD reached) (NP (CD 3) (NN cm))))) (CC or) (PP (IN for) (NP (CD 4) (NNS weeks)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (CC both) (DT the) (NP (NP (NN prevention)) (CC and) (NP (NN intervention))) (NNS experiments))) (, ,) (NP (NP (DT a) (JJ significant) (NN diminution)) (PP (IN of) (NP (NP (NN tumor) (NN size)) (CC and) (NP (NN weight))))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (DT the) (JJ drug-treated) (NNS animals)))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vivo)) (NP (JJ nuclear) (JJ magnetic) (NN resonance)) (NN analysis)) (PP (IN of) (NP (NP (NN tumor) (NN blood) (NN flow)) (PP (IN in) (NP (JJ linomide-treated) (NNS animals)))))) (VP (VBD showed) (NP (NP (NN localization)) (PP (IN of) (NP (NN blood) (NNS vessels)))) (ADVP (RB almost) (RB exclusively)) (PP (TO to) (NP (NP (DT the) (NN periphery)) (PP (IN of) (NP (NP (DT the) (ADJP (RB poorly) (VBN vascularized)) (NNS tumors)) (PP (IN with) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN of) (NP (CC both) (NP (JJ vascular) (NN functionality)) (CC and) (NP (NN vasodilation)))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Histological) (NN examination)) (PP (IN of) (NP (NP (NNS tumors)) (PP (IN from) (NP (JJ linomide-treated) (NNS animals)))))) (VP (VBD revealed) (NP (JJ marked) (NN avascularity)))) (. .)))
(S1 (S (S (NP (JJ Treated) (NNS animals)) (ADVP (RB also)) (VP (VBD displayed) (NP (NP (DT a) (JJ 2.4-fold) (NN reduction)) (PP (IN of) (NP (NP (NN tumor) (JJ vascular) (JJ endothelial) (NN growth) (NN factor)) (NN mRNA) (NNS levels)))))) (. .)))
(S1 (S (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (PRP$ our) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (PP (IN in) (NP (NN VHL) (NN disease))) (, ,) (NP (NP (NN therapy)) (VP (VBN directed) (PP (IN at) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (ADJP (RB constitutively) (VBN expressed)) (NN VEGF) (NN induction)) (PP (IN of) (NP (NN angiogenesis))) (PP (IN by) (NP (NN VHL) (NNS tumors))))))))) (VP (MD may) (VP (VB constitute) (NP (DT an) (JJ effective) (JJ medical) (NN treatment)))))))) (. .)))
